These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 25744274)

  • 1. Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol.
    Keyzer CA; de Jong MA; Fenna van Breda G; Vervloet MG; Laverman GD; Hemmelder M; Janssen WM; Lambers Heerspink HJ; Navis G; de Borst MH;
    Nephrol Dial Transplant; 2016 Jul; 31(7):1081-7. PubMed ID: 25744274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial.
    Keyzer CA; van Breda GF; Vervloet MG; de Jong MA; Laverman GD; Hemmelder MH; Janssen WM; Lambers Heerspink HJ; Kwakernaak AJ; Bakker SJ; Navis G; de Borst MH;
    J Am Soc Nephrol; 2017 Apr; 28(4):1296-1305. PubMed ID: 27856633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Dietary Sodium Restriction in Kidney Transplant Recipients Treated With Renin-Angiotensin-Aldosterone System Blockade: A Randomized Clinical Trial.
    de Vries LV; Dobrowolski LC; van den Bosch JJ; Riphagen IJ; Krediet CT; Bemelman FJ; Bakker SJ; Navis G
    Am J Kidney Dis; 2016 Jun; 67(6):936-44. PubMed ID: 26803690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
    Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
    Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.
    Parvanova A; Trillini M; Podestà MA; Iliev IP; Ruggiero B; Abbate M; Perna A; Peraro F; Diadei O; Rubis N; Gaspari F; Carrara F; Stucchi N; Belviso A; Bossi AC; Trevisan R; Remuzzi G; de Borst M; Ruggenenti P;
    Lancet Diabetes Endocrinol; 2018 Jan; 6(1):27-40. PubMed ID: 29104158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium restriction potentiates the renoprotective effects of combined vitamin D receptor activation and angiotensin-converting enzyme inhibition in established proteinuric nephropathy.
    Mirkovic K; Frenay AS; van den Born J; van Goor H; Navis G; de Borst MH;
    Nephrol Dial Transplant; 2017 Aug; 32(8):1293-1301. PubMed ID: 26311058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial.
    Kwakernaak AJ; Krikken JA; Binnenmars SH; Visser FW; Hemmelder MH; Woittiez AJ; Groen H; Laverman GD; Navis G;
    Lancet Diabetes Endocrinol; 2014 May; 2(5):385-95. PubMed ID: 24795252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.
    Slagman MC; Waanders F; Hemmelder MH; Woittiez AJ; Janssen WM; Lambers Heerspink HJ; Navis G; Laverman GD;
    BMJ; 2011 Jul; 343():d4366. PubMed ID: 21791491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of intensive low-salt diet education on albuminuria among nondiabetic patients with hypertension treated with olmesartan: a single-blinded randomized, controlled trial.
    Hwang JH; Chin HJ; Kim S; Kim DK; Kim S; Park JH; Shin SJ; Lee SH; Choi BS; Lim CS
    Clin J Am Soc Nephrol; 2014 Dec; 9(12):2059-69. PubMed ID: 25332317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels.
    Gant CM; Laverman GD; Vogt L; Slagman MCJ; Heerspink HJL; Waanders F; Hemmelder MH; Navis G;
    BMC Nephrol; 2017 Dec; 18(1):370. PubMed ID: 29262813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paricalcitol versus placebo for reduction of proteinuria in kidney transplant recipients: a double-blind, randomized controlled trial.
    Oblak M; Mlinšek G; Kandus A; Buturović-Ponikvar J; Arnol M
    Transpl Int; 2018 Dec; 31(12):1391-1404. PubMed ID: 30062716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-Analysis of the Effect of Dietary Sodium Restriction with or without Concomitant Renin-Angiotensin-Aldosterone System-Inhibiting Treatment on Albuminuria.
    D'Elia L; Rossi G; Schiano di Cola M; Savino I; Galletti F; Strazzullo P
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1542-52. PubMed ID: 26240299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
    de Zeeuw D; Agarwal R; Amdahl M; Audhya P; Coyne D; Garimella T; Parving HH; Pritchett Y; Remuzzi G; Ritz E; Andress D
    Lancet; 2010 Nov; 376(9752):1543-51. PubMed ID: 21055801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients.
    Slagman MC; Waanders F; Vogt L; Damman K; Hemmelder M; Navis G; Laverman GD
    Nephrol Dial Transplant; 2012 Mar; 27(3):983-90. PubMed ID: 21862455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of dietary sodium restriction in the management of chronic kidney disease.
    Krikken JA; Laverman GD; Navis G
    Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):531-8. PubMed ID: 19713840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA; Gariani K; Martin PY
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients.
    Kwakernaak AJ; Waanders F; Slagman MC; Dokter MM; Laverman GD; de Boer RA; Navis G
    J Hypertens; 2013 Dec; 31(12):2425-32. PubMed ID: 24029871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial.
    Larsen T; Mose FH; Bech JN; Pedersen EB
    BMC Nephrol; 2013 Jul; 14():163. PubMed ID: 23889806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial.
    Taheri S; Asim M; Al Malki H; Fituri O; Suthanthiran M; August P;
    Trials; 2018 Apr; 19(1):230. PubMed ID: 29665833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.